Analytical Data
-
Gene name
CRX
- Application
-
Alternative Names
CORD2
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O43186
-
Expression Region
1-299aa
-
Molecular Weight
39.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CRX (Cone-Rod Homeobox) is a transcription factor critical for the development and function of photoreceptor cells in the retina, playing a pivotal role in the regulation of visual phototransduction pathways. Mutations in the CRX gene are associated with various inherited retinal degenerative diseases, such as Leber congenital amaurosis and retinitis pigmentosa, leading to severe vision impairment or blindness. The study of CRX recombinant proteins has garnered significant interest in the field of molecular and cell biology due to its potential therapeutic implications. By producing and characterizing CRX protein in vitro, researchers aim to elucidate the molecular mechanisms underlying its transcriptional regulation and to explore the possibility of gene therapy approaches for retinal diseases caused by CRX mutations. Furthermore, understanding the structure-function relationship of CRX can aid in the design of small molecules or peptides that could modulate its activity, offering new avenues for intervention in retinal disorders. The development of CRX recombinant protein also provides a valuable tool for screening potential drug candidates and for investigating the interactions between CRX and its downstream targets, thus contributing to the broader understanding of retinal biology and pathology. Overall, research on CRX and its recombinant proteins holds the promise of advancing therapeutic strategies for genetic retinal diseases, highlighting the importance of continued exploration in this area of study.
